Compare Becton Dickinson and Co (BDX) vs Harley-Davidson Inc (HOG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Becton Dickinson and Co vs Harley-Davidson Inc — how do they compare? Becton Dickinson and Co trades at $154.29 (market cap $41.51B), while Harley-Davidson Inc trades at $25.4 (market cap $2.64B). The key difference: Becton Dickinson and Co is far larger — about 15.7× Harley-Davidson Inc's market cap, and Harley-Davidson Inc pays the higher dividend (2.93%). Which is the better fit depends on your goals.
| BDX | HOG | |
|---|---|---|
Market Cap | $41.51B | $2.64B |
Sector | Health | Consumer Cyclical |
52-Week High | $185.39 | $31.03 |
52-Week Low | $135.49 | $17.19 |
Enterprise Value | $57.97B | $3.04B |
Dividend Yield | 2.79% | 2.93% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BDX trades at $153.83, up 1.24% today, with technical indicators showing a neutral to bullish bias. The company has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $2.90 exceeding expectations. Revenue growth remains steady, reaching $21.84B in 2025, though net margins have compressed to 5.12%. Recent news highlights BDX's innovation in medical technology and positive analyst sentiment.
The outlook for BDX appears balanced. Upside potential exists from continued earnings beats and strategic positioning in growing healthcare segments like GLP-1 drug support equipment. However, risks include margin pressure, elevated debt levels, and cautious hospital spending. The consensus price target of $173.40 suggests moderate upside from current levels.
Harley-Davidson (HOG) trades at $25.39, up 0.99% with a bullish technical signal from moving averages. The stock shows mixed fundamentals with declining revenue from $5.8B in 2022 to $4.5B in 2025 and net income dropping to $339M, though valuation ratios remain attractive with P/E of 13.16 and P/B of 0.87. Recent news highlights production returning to US facilities and Q2 2026 earnings scheduled for July 23, 2026.
The outlook is cautiously optimistic with analyst consensus at Hold (65.71%) and price target of $23.40 below current price. Key opportunities include cost cuts and US production shift, while risks involve margin pressure and competitive threats. The stock faces headwinds from recent earnings misses but maintains dividend payments and institutional interest.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Becton Dickinson and Co
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.
Read more on BDX →About Harley-Davidson Inc
Harley-Davidson is a global leading manufacturer of heavyweight motorcycles, merchandise, parts, and accessories. It sells custom, cruiser, and touring motorcycles and offers a complete line of Harley-Davidson motorcycle parts, accessories, riding gear, and apparel, as well as merchandise. Harley-Davidson Financial Services provides wholesale financing to dealers and retail financing and insurance brokerage services to customers. Harley has historically captured about half of all heavyweight domestic retail motorcycle registrations, a metric it had ceded in 2020 as it repositioned the business, but a level it is working back toward. In recent years the firm has expanded into the adventure touring market with its Pan America model and into electric with the LiveWire brand.
Read more on HOG →
